CytomX Therapeutics Inc (NASDAQ:CTMX) – Stock analysts at Cantor Fitzgerald boosted their FY2018 EPS estimates for shares of CytomX Therapeutics in a research report issued to clients and investors on Tuesday. Cantor Fitzgerald analyst M. Goldstein now expects that the biotechnology company will post earnings of ($1.48) per share for the year, up from their previous forecast of ($1.56). Cantor Fitzgerald has a “Buy” rating and a $40.00 price objective on the stock.
Other research analysts have also recently issued research reports about the stock. BidaskClub upgraded shares of CytomX Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, December 15th. Zacks Investment Research cut shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, February 12th. Jefferies Group lifted their price target on shares of CytomX Therapeutics to $40.00 and gave the stock a “buy” rating in a research note on Thursday, March 8th. ValuEngine cut shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, Citigroup began coverage on shares of CytomX Therapeutics in a research note on Friday, January 5th. They set a “buy” rating and a $40.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $36.13.
Hedge funds have recently made changes to their positions in the company. Perceptive Advisors LLC increased its holdings in CytomX Therapeutics by 79.1% in the 4th quarter. Perceptive Advisors LLC now owns 2,490,381 shares of the biotechnology company’s stock valued at $52,571,000 after acquiring an additional 1,100,000 shares during the last quarter. BlackRock Inc. increased its holdings in CytomX Therapeutics by 28.5% in the 4th quarter. BlackRock Inc. now owns 2,646,599 shares of the biotechnology company’s stock valued at $55,870,000 after acquiring an additional 586,698 shares during the last quarter. Millennium Management LLC increased its holdings in CytomX Therapeutics by 34.0% in the 4th quarter. Millennium Management LLC now owns 837,415 shares of the biotechnology company’s stock valued at $17,678,000 after acquiring an additional 212,423 shares during the last quarter. Nexthera Capital LP bought a new stake in CytomX Therapeutics in the 4th quarter valued at $3,797,000. Finally, Renaissance Technologies LLC increased its holdings in CytomX Therapeutics by 32.9% in the 4th quarter. Renaissance Technologies LLC now owns 715,100 shares of the biotechnology company’s stock valued at $15,096,000 after acquiring an additional 177,200 shares during the last quarter. Hedge funds and other institutional investors own 78.07% of the company’s stock.
In other news, Director Frederick W. Gluck sold 5,000 shares of the firm’s stock in a transaction on Tuesday, December 26th. The shares were sold at an average price of $22.29, for a total transaction of $111,450.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Debanjan Ray sold 2,500 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $21.11, for a total transaction of $52,775.00. The disclosure for this sale can be found here. Insiders have sold a total of 132,626 shares of company stock worth $3,709,830 over the last 90 days. Insiders own 4.70% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “FY2018 EPS Estimates for CytomX Therapeutics Inc Raised by Analyst (CTMX)” was published by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3297806/fy2018-eps-estimates-for-cytomx-therapeutics-inc-raised-by-analyst-ctmx.html.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.